IL315945A - Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof - Google Patents

Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

Info

Publication number
IL315945A
IL315945A IL315945A IL31594524A IL315945A IL 315945 A IL315945 A IL 315945A IL 315945 A IL315945 A IL 315945A IL 31594524 A IL31594524 A IL 31594524A IL 315945 A IL315945 A IL 315945A
Authority
IL
Israel
Prior art keywords
antagonists
inverse agonists
cannabinoid receptor
cannabinoid
agonists
Prior art date
Application number
IL315945A
Other languages
English (en)
Hebrew (he)
Inventor
Marshall Morningstar
Zhuang Jin
Hongfeng Deng
Original Assignee
Corbus Pharmaceuticals Inc
Marshall Morningstar
Zhuang Jin
Hongfeng Deng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc, Marshall Morningstar, Zhuang Jin, Hongfeng Deng filed Critical Corbus Pharmaceuticals Inc
Publication of IL315945A publication Critical patent/IL315945A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315945A 2022-04-07 2023-04-07 Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof IL315945A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328611P 2022-04-07 2022-04-07
US202363439645P 2023-01-18 2023-01-18
PCT/US2023/017817 WO2023196556A1 (en) 2022-04-07 2023-04-07 Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

Publications (1)

Publication Number Publication Date
IL315945A true IL315945A (en) 2024-11-01

Family

ID=88243528

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315945A IL315945A (en) 2022-04-07 2023-04-07 Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

Country Status (12)

Country Link
US (1) US20250248973A1 (https=)
EP (1) EP4504179A4 (https=)
JP (1) JP2025512995A (https=)
KR (1) KR20250008741A (https=)
CN (1) CN119325378A (https=)
AU (1) AU2023250955A1 (https=)
CA (1) CA3255170A1 (https=)
GB (1) GB2633943A (https=)
IL (1) IL315945A (https=)
MX (1) MX2024012263A (https=)
WO (1) WO2023196556A1 (https=)
ZA (1) ZA202407552B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025040089A1 (zh) * 2023-08-21 2025-02-27 德睿智药(苏州)新药研发有限公司 用于选择性调节大麻素cb1功能的新型杂环类化合物
WO2025103493A1 (zh) * 2023-11-16 2025-05-22 西藏海思科制药有限公司 一种大麻素受体1拮抗剂及其应用
WO2025185689A1 (zh) * 2024-03-08 2025-09-12 成都轻胜生物医药科技有限公司 吡唑衍生物及其用途
CN118580162A (zh) * 2024-05-27 2024-09-03 中国药科大学 一种酰肼类化合物及无金属策略促进酰肼类化合物制备的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL363751A1 (en) * 2001-03-22 2004-11-29 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
US7655685B2 (en) * 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US8580768B2 (en) * 2010-11-18 2013-11-12 Jenrin Discovery, Inc. Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
KR20150113762A (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 황 작용기를 포함하는 4,5-다이하이드로-1h-피라졸-3-카복스이미드아마이드 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
US12286405B2 (en) * 2019-05-17 2025-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scalable synthesis of dual-target inhibitor of cannabinoid-1 receptor and inducible nitric oxide synthase

Also Published As

Publication number Publication date
CN119325378A (zh) 2025-01-17
US20250248973A1 (en) 2025-08-07
GB202416413D0 (en) 2024-12-25
WO2023196556A1 (en) 2023-10-12
CA3255170A1 (en) 2023-10-12
AU2023250955A1 (en) 2024-10-17
GB2633943A (en) 2025-03-26
KR20250008741A (ko) 2025-01-15
MX2024012263A (es) 2025-01-09
JP2025512995A (ja) 2025-04-22
EP4504179A1 (en) 2025-02-12
ZA202407552B (en) 2025-12-17
EP4504179A4 (en) 2026-01-07

Similar Documents

Publication Publication Date Title
GB202416413D0 (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
PL4212527T3 (pl) Związek będący agonistą receptora GLP-1R i jego zastosowanie
IL304521A (en) GPCR receptor agonists, pharmaceutical preparations containing them and methods of using them
EP4227299A4 (en) GLP-1 RECEPTOR AGONIST, BENZIMIDAZOLONE AND ITS USE
EP4317142A4 (en) THIOPHENE-TYPE GLP-1 RECEPTOR AGONIST AND ITS USE
MXPA04002140A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico.
IL308099A (en) Orexin receptor agonists and uses thereof
DK4058445T3 (da) Glp-1-receptoragonist og anvendelse deraf
EP4361145A4 (en) Glp-1 receptor agonist and composition and use thereof
IL304574A (en) Glucagon-like peptide 1 receptor agonists and uses thereof
IL160837A0 (en) Toll-like receptor 3 signaling agonists and antagonists
ZA200409333B (en) 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2B and alpha-2C adrenergic receptors.
IL281471A (en) Farnesoid x receptor agonists and uses thereof
HUE068662T2 (hu) Angiotenzin-ii-receptor-2 agonista új alkalmazása
SMT202600076T1 (it) Agonisti del recettore farnesoide x e loro uso
EP4262788A4 (en) UREA-OREXIN RECEPTOR AGONISTS
IL309108A (en) Orexin sulfonamide receptor agonists and uses thereof
SG11202010388SA (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
ZA202101246B (en) Cd200r agonist antibodies and uses thereof
JOP20250091A1 (ar) منبهات مستقبلات السوماتوستاتين 2 واستخداماتها
EP4490187A4 (en) EPO RECEPTOR AGONISTS AND ANTAGONISTS
AU2023409874A1 (en) Cannabinoid receptor 1 antagonists and uses
CA3276876A1 (en) Cannabinoid receptor 1 antagonists and uses
HK40126536A (en) Cannabinoid receptor 1 antagonists and uses
CA3271748A1 (en) Somatostatin receptor 2 agonists and uses thereof